Anti-CD8, Recombinant [14]
Invented at Cancer Research UK London Research Institute: Lincoln's Inn Fields
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 153256 |
| Applications | ELISA FACS IHC IP WB |
| Antigen/Gene or Protein Targets | CD8 |
| Synonyms | Leu2 |
| Reactivity | Human |
| Relevance | CD8 is a T cell co-receptor that recognises, together with the T cell receptor, MHC class I molecules. CD8 is present on human suppressor / cytotoxic T cells, 30% of circulating T cells. Clone 14 is recommended for: the detection of immunoregulatory T cell subset imbalances in autoimmune disorders and immunodeficiency states, categorisation of T cell acute lymphoblastic leukaemia and lymphoblastic lymphoma in conjunction with other antigens and determination of CD4/CD8 ratios in immune deficiencies, rheumatoid arthritis and multiple sclerosis. |
| Host | Mouse |
| Immunogen | Fibronectin-purified human monocytes |
| Subclass | IgG1 |
| Formulation | PBS |
| Concentration | 1mgml-1 |
| Research Area | Immunology |
| Notes |
Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma. Five products based on this clone: - Anti-CD8 [14], Mouse IgG1, Kappa - Anti-CD8 [14], Rabbit IgG, Kappa - Anti-CD8 [14], Human IgG1, Kappa - Anti-CD8 [14], Human IgG1, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors - Anti-CD8 [14], Human IgG4-S228P, Kappa |
References: 1 entry
Original hybridoma first published in: Hogg et al. 1999. J Clin Invest. 103(1):97-106. PMID: 9884339.
Add a reference
References: 1 entry
Original hybridoma first published in: Hogg et al. 1999. J Clin Invest. 103(1):97-106. PMID: 9884339.
Add a reference
